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ABSTRACT
Introduction: Gastrointestinal dysmotility and
constipation are common problems in intensive care
patients. The majority of critical care patients are
sedated with opioids to facilitate tolerance of
endotracheal tubes and mechanical ventilation, which
inhibit gastrointestinal motility and lead to adverse
outcomes. Methylnaltrexone is a peripheral opioid
antagonist that does not cross the blood–brain barrier
and can reverse the peripheral side effects of opioids
without affecting the desired central properties. This
trial will investigate whether methylnaltrexone can
reverse opioid-induced constipation and
gastrointestinal dysmotility.
Methods: This is a single-centre, multisite, double-
blind, randomised, placebo-controlled trial. 84 patients
will be recruited from 4 intensive care units (ICUs)
within Imperial College Healthcare NHS Trust. Patients
will receive intravenous methylnaltrexone or placebo on
a daily basis if they are receiving opioid infusion to
facilitate mechanical ventilation and have not opened
their bowels for 48 hours. All patients will receive
standard laxatives as per the clinical ICU bowel
protocol prior to randomisation. The primary outcome
of the trial will be time to significant rescue-free
laxation following randomisation. Secondary outcomes
will include tolerance of enteral feed, gastric residual
volumes, incidence of pneumonia, blood stream and
Clostridium difficile infection, and any reversal of
central opioid effects.
Ethics and dissemination: The trial protocol, the
patient/legal representative information sheets and
consent forms have been reviewed and approved by
the Harrow Research Ethics Committee (REC Reference
14/LO/2004). An independent Trial Steering Committee
and Data Monitoring Committee are in place, with
patient representation. On completion, the trial results
will be published in peer-reviewed journals and
presented at national and international scientific
meetings.
Trial registration number: 2014-004687-37;
Pre-results.
INTRODUCTION
Background and rationale
Bowel dysfunction in the intensive care unit
(ICU) represents an important problem in
critical care, with up to 70% of patients suf-
fering from constipation.1 There is increas-
ing evidence that opioids contribute to
perioperative and ICU bowel dysfunction.2
Other studies demonstrate that bowel dys-
function in the critically ill is associated with
adverse outcomes including delay in gastric
emptying leading to increased gastro-
oesophageal reﬂux and aspiration, decreased
enteral feeding, delayed ICU discharge and
increased mortality.3–5 While bowel dysfunc-
tion in critically ill patients is multifactorial
and some component is due to the general
effects of complex critical illness, exogenous
and endogenous opioids contribute to this
bowel dysmotility.6 Restoration of normal
gastrointestinal (GI) function is essential for
establishing enteral feeding; it also protects
against the bacterial translocation, alleviates
GI discomfort due to constipation and short-
ens ICU stay.7
Potential therapeutic inroads have been
made in addressing this problem. Naloxone,
a competitive opioid antagonist, is most
commonly administered systemically to
Strengths and limitations of this study
▪ Double-blind, placebo-controlled, randomised trial.
▪ Testing methylnaltrexone to treat an important
patient-focused outcome (constipation and
gastrointestinal stasis) in critical care.
▪ Limited sample size to answer other clinical
outcomes.
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counteract the central and peripheral effects of opioids.
When administered enterally in high doses, naloxone
has been found to have beneﬁt in the critical care
setting, with improved gastric emptying and reduced
ventilator-associated pneumonia rates.8 Unfortunately in
clinical practice, the use of naloxone is limited with
large doses required when administered enterally, and
the fact that a large proportion of those with gastric
stasis are unable to tolerate the nasogastric naloxone
itself. Of course, administering the drug via any other
route would antagonise the desired central therapeutic
effects (analgesia and sedation) in critical care patients.
Methylnaltrexone is a recently approved peripheral
μ-opioid receptor antagonist. It is a quaternary ammo-
nium compound with a positive charge, which limits its
ability to cross the blood–brain barrier. Unlike tertiary
opioid antagonists such as naloxone or naltrexone,
methylnaltrexone does not reverse centrally mediated
analgesia or precipitate withdrawal. It is commercially
available in preﬁlled syringes as a sterile, clear and col-
ourless to pale yellow aqueous solution (Salix
Pharmaceuticals, Raleigh, North Carolina, USA). The
chemical name for methylnaltrexone bromide is
(R)-N-(cyclopropylmethyl) noroxymorphone methobro-
mide. The molecular formula is C21H26NO4Br, and the
molecular weight is 436.36.
The efﬁcacy and safety of methylnaltrexone in the
treatment of opioid-induced constipation (OIC) have
been evaluated in two multicentre, randomised, double-
blind, placebo-controlled phase III trials involving adults
with advanced illness (life expectancy of 1–6 months)
who were receiving palliative care.9 10 The majority of
patients had incurable cancer, but other diagnoses
included cardiovascular disease, chronic obstructive pul-
monary disease or emphysema and Alzheimer’s disease
or dementia.
Trial inclusion criteria included patients taking stable
doses of opioids and laxatives for ≥3 days and subse-
quent OIC. Throughout all study periods, patients main-
tained their usual laxative regimen. The primary end
points were rescue-free laxation, deﬁned as a bowel
movement within 4 hours of the ﬁrst dose of methylnal-
trexone. Secondary end points included time to laxa-
tion, pain scores, opioid withdrawal symptoms and
adverse events.
The landmark published trial,9 compared methylnal-
trexone 0.15 mg/kg (n=62) with placebo (n=71), admi-
nistered on alternate days for 2 weeks. In the second
week, the dose was increased to 0.3 mg/kg if the patient
had fewer than three bowel openings by day 8.
Methylnaltrexone improved the laxation rate within
4 hours of the ﬁrst dose compared with placebo (48% vs
15% (p <0.001)). Of the patients who did respond
within 4 hours of the ﬁrst dose, half responded within
30 min. The study also showed that 52% of all patients
taking methylnaltrexone had rescue-free laxation within
4 hours, when compared with 8% in the placebo group
(p<0.001).
The efﬁcacy of methylnaltrexone in the palliative care
setting has been further conﬁrmed, with a study that
compared single subcutaneous doses of methylnaltrex-
one 0.15 mg/kg (n=47) or 0.30 mg/kg (n=55) with
placebo (n=52).10 Methylnaltrexone signiﬁcantly
improved the laxation rate within 4 hours of dosing
(62% for 0.15 mg/kg and 58% for 0.30 mg/kg vs 14%
for placebo (p<0.0001 for each dose vs placebo)). The
median time to laxation was shorter in the group admi-
nistered methylnaltrexone (70 and 45 min for the 0.15
and 0.30 mg/kg groups, respectively, compared with
placebo (>24 hours) (p<0.0001 for each dose vs
placebo)).
While methylnaltrexone is approved for the treatment
of OIC in advanced illness in palliative care patients, its
use in the medical ICU has been limited and largely
anecdotal. Case reports have reported an immediate
effect of methylnaltrexone administration on bowel
motility. In one report, methylnaltrexone was given intra-
venously to a critically ill patient with signiﬁcant burns.11
The purpose of that use was to facilitate feeding,
although bowel motility was also restored. After 4 days of
no appreciable bowel function, there was instantaneous
improvement in bowel sounds, ﬂatus, gastric residuals
and subsequently feeding. In another case, a patient
with a palliative stoma and a long history of heroin
abuse demonstrated no bowel function and signiﬁcant
distension 7 days after stoma formation.12 Within 15 min
of methylnaltrexone (subcutaneous injection), there was
a brisk output of over 1 L from the stoma. Both of these
patients were receiving high doses of opioids.
Additionally, a recent case report in a critically ill
neonate with complex congenital heart disease compli-
cated by 8 days of bowel dysmotility following ileosig-
moid anastomosis demonstrated that methylnaltrexone
(0.15 mg/kg subcutaneously) restored bowel function
within 15 min of injection.13 The child was receiving a
fentanyl infusion of 2 µg/kg/hour. A further case series
was presented as an abstract, with patients from burns,
cardiac and surgical ICUs being successfully treated with
methylnaltrexone subcutaneous injections.14 These cases
suggest that methylnaltrexone may signiﬁcantly alleviate
bowel dysfunction associated with the use of high doses
of opioids in ICU patients.
In addition, we carried out a retrospective chart review
of 88 non-surgical critical care patients receiving fen-
tanyl infusions at the Hammersmith Hospital, Imperial
College Healthcare NHS Trust over a 10-week period
(1 September—15 November 2009).15 Fifteen patients
met the criteria of failure to laxate within 72 hours
despite treatment with senna and sodium docusate.
Eight of these patients subsequently received conven-
tional rescue therapy (combination of sodium picosul-
fate (5 mg) and two glycerin suppositories (4 g)), while
seven patients received methylnaltrexone (subcutaneous
injection, 0.15 mg/kg). Six of seven methylnaltrexone
patients responded to one or two doses with laxation
within 24 hours versus 0/8 for conventional rescue
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therapy (p=0.001). All methylnaltrexone patients, but
only 4/8 of patients administered conventional rescue
therapy, progressed to full target enteral feeding
(p=0.076) within 24 hours. ICU mortality was 2/7 for
methylnaltrexone vs 4/8 for standard therapy (p=0.61).
There were no adverse effects from either rescue laxative
therapies. These encouraging results further support the
use of methylnaltrexone in critical care patients.
The use of opioids can also have an impact on infec-
tion. Exogenous opioids are known to have inhibitory
effects on immune responses including T-lymphocyte
function,16 B-lymphocyte function,17 natural killer cell
activity18 as well as mononuclear cell proliferation, differ-
entiation19 and phagocytosis.20
Thus, opioids may modulate the immune response
through interaction with their receptors. As well as
being present centrally, these receptors have been
identiﬁed in peripheral nerves, and their endogenous
peptide ligand is expressed on granulocytes, macro-
phages and lymphocytes.21 While yet to be established,
the general effect of opioids is thought to be
immunosuppressive.22
Infection is a major problem in critically ill patients
with up to 37.4% of patients demonstrating sepsis in ICU.
Common organisms include Staphylococcus aureus (30%,
including 14% methicillin resistance), Pseudomonas spp
(14%) and Escherichia coli (13%). Pseudomonas spp have
been shown to be independently associated with
increased mortality rates.23 Patients with sepsis have more
severe organ dysfunction, longer ICU and hospital
lengths of stay, and higher mortality rate than patients
without sepsis. In animal studies, direct exposure of
Pseudomonas aeruginosa to morphine in vitro showed that
morphine transforms the bacteria to a more virulent
phenotype that is attenuated in part by methylnaltrex-
one.24 If the peripheral effects of opioids are reversed in
critical care patients, there could be an even more dra-
matic improvement in infection and patient outcome
compared to simply reversing the GI side effects.
There are considerable safety data available on the use
of methylnaltrexone. In phase III trials,9 10 subcutaneous
methylnaltrexone was well tolerated in patents with OIC
and an advanced illness. The most common adverse
effects reported for all doses of methylnaltrexone are
abdominal pain, nausea, diarrhoea, ﬂatulence, dizziness,
injection site reactions and hyperhidrosis. None of the
reported serious adverse events (SAEs) were attributed
to the study drug.
Rare cases of GI perforation have been reported in
patients with advanced illness and conditions that may
be associated with localised or diffuse reduction of struc-
tural integrity in the wall of the GI tract (ie, cancer,
peptic ulcer and Ogilvie’s syndrome). Perforations have
involved varying regions of the GI tract, for example,
stomach, duodenum and colon.25 The Food and Drug
Administration (FDA) recommends that methylnaltrex-
one is used with caution in patients with known or sus-
pected lesions of the GI tract and is contraindicated in
bowel obstruction and acute abdominal illness. Therapy
should be discontinued if patients develop severe, per-
sistent and/or worsening abdominal symptoms.26
There was no evidence of systemic opioid withdrawal
or signiﬁcant changes in pain scores throughout the
phase III studies in palliative care or the retrospective
pilot study in critical care.15
Methylnaltrexone is licensed for subcutaneous
administration in palliative care patients as these
groups of patients do not routinely have intravenous
access and it can be self-administered subcutaneously.
Many trials and case reports have demonstrated that
intravenous administration is safe and efﬁca-
cious.11 27 28 The pharmacokinetics of intravenous
administration are well understood and predictable.
In healthy volunteers, repeated administration of
intravenous methylnaltrexone is well tolerated, with
no signiﬁcant adverse events or changes in opioid sub-
jective ratings and no clinically noteworthy alterations
in pharmacokinetics.29 In the ICU, all patients have
intravenous catheter in place with 1:1 nursing, and
furthermore, many are oedematous due to their
underlying critical illness, justifying the use of the
intravenous route as more appropriate.
Therefore, the rationale for the current study is that
constipation and gut dysfunction are a major concern in
intensive care patients. Reversal of this would lead to
patient beneﬁt.30 Methylnaltrexone has been shown to
be beneﬁcial in treating OIC in patients with advanced
illness who are receiving palliative care when response to
laxatives has not been sufﬁcient.9 We hope to replicate
the beneﬁcial effects of methylnaltrexone in ICU
patients. There may also be additional beneﬁts in redu-
cing infection and immunosuppression, and hence an
overall improvement in patient outcome.
Objectives
The primary objective of the study is to assess the efﬁ-
cacy of methylnaltrexone in inducing laxation in ICU
patients sedated with opioid infusions.
The secondary objectives include observing whether
the use of methylnaltrexone leads to increased opioid
requirements through central nervous system penetra-
tion and antagonism, and assessing whether there are
additional beneﬁts such as reduced gastric stasis,
improved enteral feeding and a reduction in infection;
and ﬁnally to assess the safety and side effect proﬁle of
intravenous methylnaltrexone in ICU patients.
Plasma and serum will also be stored and further ana-
lysed for cytokine levels, metabolic proﬁles and leuco-
cyte function assays performed to further investigate the
mechanism of the immune effects of opiates and subse-
quent reversal.
Trial design
The study is an interventional, double-blind, rando-
mised, placebo-controlled trial (see ﬁgure 1).
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METHODS: PARTICIPANTS, INTERVENTIONS AND
OUTCOMES
Study setting
The study will be conducted in the ICUs within Imperial
College Healthcare NHS Trust. The three hospitals are ter-
tiary academic centres: Hammersmith Hospital, Charing
Cross Hospital and St. Mary’s Hospital. Further ICUs
across other NHS Trusts may be considered at a later date.
Eligibility criteria
All patients who are clinically constipated and receiving
an opioid infusion will be screened against the inclusion
and exclusion criteria for eligibility of the study.
The inclusion criteria are as follows:
▸ Men and women aged ≥18 years.
▸ Following ICU admission, sedated with opioids and
requiring invasive ventilator support.
▸ Scheduled for continuous infusion/administration of
opioid analgesics for at least a further 24 hours.
▸ Constipated (not opened bowels for a minimum
48 hours).
▸ Access for enteral administration of medications and
gastric tube feeds.
▸ Initiation of gastric tube feeds.
▸ Patient weight of 38–114 kg (this allows pre prepar-
ation of drug with either 8 or 12 mg).
The exclusion criteria are as follows:
▸ Known to be pregnant.
▸ Patients with end-stage renal failure requiring dialysis
prior to admission.
▸ Diarrhoea on admission.
▸ GI tract surgery within 8 weeks prior to ICU admission.
▸ Presence of ileostomy or colostomy.
▸ Mechanical GI obstruction.
▸ Suspected acute surgical abdomen.
▸ History of Crohn’s disease or ulcerative colitis.
▸ Receiving palliative care or not expected to survive
>12 hours.
▸ Severe chronic hepatic impairment (Child Pugh Class C).
▸ Suspected hepatic encephalopathy.
▸ Known to have received another investigational medi-
cinal product within 30 days or currently in another
interventional trial that might interact with the study
drug or previously enrolled into MOTION.
▸ Known hypersensitivity to the study drug or any of its
excipients.
Figure 1 Flow chart. Adult critically ill patients sedated with and expected to remain on opioids for a further 24 hours, who have
not opened their bowels for 48 hours. All patients are receiving standard ICU bowel care.
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Interventions
All patients will be sedated to facilitate mechanical venti-
lation. The standard sedative regimens of the ICU will
be followed, titrated by the bedside nurse and clinical
team to the patient’s need and the RASS (Richmond
Agitation Sedation Score). The standard sedation will
include an opioid (remifentanyl, fentanyl or morphine)
and a hypnotic agent (propofol or midazolam).
All patients will be receiving standard ICU bowel care
prior to study enrolment as part of the departmental
bowel care policy.
Patients will be randomised to either treatment group
or control group. The patient will remain in this group
for the duration of the study.
Treatment group
▸ As per the Summary of Product Characteristics,
patients weighing 38–61 kg will receive 8 mg (0.4 mL)
methylnaltrexone diluted in 50 mL of 0.9% saline.
▸ Patients weighing 62–114 kg will receive 12 mg
(0.6 mL) methylnaltrexone diluted in 50 mL of 0.9%
saline.
▸ Treatment will be administered over 15 min via an
indwelling intravenous catheter. The dose will be
based on estimated actual body weight.
Control group
▸ Placebo (saline) prepared in identical syringes to
study drug containing 50.4 or 50.6 mL of 0.9% saline.
▸ Placebo will be administered over 15 min via an
indwelling intravenous catheter.
All patients
▸ The study drugs will be supplied to the ICU by phar-
macy as speciﬁc research study drugs and they will be
stored in separate research cupboards at room tem-
perature. The study drug will be drawn up, labelled
and administered by the research nurse on duty at
that site. He/she will be non-blinded for the remain-
der of the study. He/she will not be involved in moni-
toring or collecting clinical outcome data.
▸ The study outcome measures are routinely collected
and recorded by the bedside nurses and medical
team, who will remain blinded to treatment allocation
for the duration of the study. The study drug (active
drug or placebo) will be prescribed on the patient
drug chart by the clinical staff as per each ICU’s
policy, with blinding maintained.
▸ The patient will continue to receive the study drug at
the same time on a daily basis, until the patient has
been free of opioids for 24 hours or at 28 days.
Rescue therapy
▸ If a patient allocated to either arm fails to open their
bowels within 72 hours of receiving study infusion,
then rescue laxatives of a combination of sodium
picosulfate (5 mg) and two glycerin suppositories
(4 g) will be administered. The patient will continue
to receive the study drug.
Other therapy
▸ If patients have high gastric aspirates and are not
deemed to be absorbing enteral feed, then they will
be administered prokinetics (erythromycin 250 mg
intravenous four times a day and metoclopramide
10 mg intravenous three times a day) as per standard
ICU protocol. These will be prescribed by the treating
clinicians (blinded to study drug).
▸ All patients will receive the standard hospital
approved enteral feed administered to a target infu-
sion rate calculated by the treating ICU dietician.
Withholding study drug
▸ If the patient develops diarrhoea or severe, persistent
and/or worsening abdominal symptoms, then the
standard ICU bowel care will be given and the study
drug will be stopped. Stool will be sent to microbiol-
ogy laboratories for culture and testing for Clostridium
difﬁcile toxin, if an infective cause is thought clinically
likely. The incidence of diarrhoea and C. difﬁcile
infection is a secondary outcome. Patients will con-
tinue in the study, unless consent is withdrawn, and
be followed for other end points as part of full ana-
lysis and to complete the blood sampling timetable.
Dose modiﬁcations for toxicity
▸ In patients with severe renal impairment (estimated
glomerular ﬁltration rate (eGFR) <30 mL/min), the
dose of methylnaltrexone administered will be
reduced to
– 38–61 kg: 4 mg
– 62–114 kg: 8 mg
– Patients who are receiving continuous veno–venous
haemoﬁltration will receive the normal dose.
– The normal dose can be given in mild hepatic
impairment, but the study drug is not licensed in
severe hepatic impairment (Child Pugh Class C).
– Participants will be followed up daily while on the
ICU. Routinely collected clinical data (cardiovascu-
lar, respiratory and renal physiological variables as
well as haematological, biochemical and microbio-
logical blood test results) will be recorded on a
daily basis during this time.
– Patients will also be followed up to ascertain survival
status at 28 days postrecruitment and at hospital
discharge.
Outcomes
The primary outcome is time to signiﬁcant rescue-free
laxation following randomisation. Signiﬁcant laxation is
deﬁned as stool volume of >100 mL, as estimated by the
attending nurse.
Secondary outcomes include
▸ Gastric residual volume measured every 4 hours and
totalled over 24 hours.
▸ Toleration of enteral feeds: daily assessment of percent-
age of patients achieving full target enteral feeding.
▸ Requirement of rescue laxatives: 1/2 sachet picolax
(5 mg sodium picosulfate) and two glycerin supposi-
tories (4 g mould).
▸ Requirement of prokinetics (10 mg metoclopramide
three times a day, 250 mg erythromycin four times a
day).
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▸ Average number of bowel movements per day.
▸ Escalation of opioid dose due to antagonism/reversal
of analgesia and sedation.
▸ Incidence of ventilator-associated pneumonia,
deﬁned by the Clinical Pulmonary Infection Score.
▸ Incidence of diarrhoea.
▸ Incidence of C. difﬁcile infection: PCR or toxin
positive.
▸ Incidence of positive microbiology blood cultures.
▸ Mortality: 28 days, ICU and hospital.
Exploratory mechanistic outcomes include
▸ Sepsis biomarkers.
▸ Leucocyte function tests
▸ Leucocyte migration assays.
Participant timeline
See table 1.
Sample size
The sample size will be 84 patients. The primary end
point is time to rescue-free laxation. In a phase III trial in
palliative care patients, 48% of participants receiving
methylnaltrexone had rescue-free laxation within 4 hours
compared to 15% in the placebo arm, p<0.001.8 Pilot
data in ICU patients suggest that a difference in efﬁcacy
of this magnitude would be reasonable in the ICU setting
(71% vs 0% opened bowels within 12 hours).14 Allowing
for a drop-out rate of 5% (patients who withdraw consent
after regaining consciousness), with 42 participants in
each arm (26 events in total), this study will have 85%
power to detect a difference of 33% (15% vs 48%) in the
proportion of patients with rescue-free laxation within
12 hours at the 5% level (using a two-tailed log-rank test).
This calculation assumes that at the time of analysis, 65%
of observations will be censored (either due to withdrawal
or rescue), which is likely to be a considerable overesti-
mate since those with rescue-free laxation occurring after
12 hours will also be events. We have nevertheless main-
tained the sample size at 42 per group, in order to ensure
the generalisability of results. The recruitment target will
therefore be 84 patients.
Recruitment
Patients will be reviewed on a daily basis by the unit
research nurse. All patients who are clinically consti-
pated and on opioid infusion will be screened against
the inclusion and exclusion criteria for eligibility of the
study. The initial screening will take place following
24 hours of constipation following admission and opioid
infusion. This will then allow for at least another
24 hours to check eligibility criteria and consent from
the personal legal representative (PerLR).
METHODS: ASSIGNMENT OF INTERVENTIONS
Allocation
Randomisation lists (one per ICU) will be prepared
using 1:1 allocation (methylnaltrexone vs placebo) by
Table 1 Visit schedule
Visit Day −1 Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 Days 6–28
Screening X X*
Informed consent† PerLR/ProLR assent will be obtained
initially. This can be done from
24 hours of constipation following
admission (though the patient would
not be randomised until at least
48 hours have passed).
Retrospective patient consent will be
obtained when the patient has
recovered
Inclusion/exclusion criteria X X*
Randomisation X
Study drug administration Study drug administered daily until
patient has been off opioid
sedation for 24 hours or at 28 days
Blood sampling (15–30 mL) X X X X X X One further blood
sample taken at
24 hours postcessation
of opioid infusion
Daily collection of clinical data X X X X X X X
Final visit Until patient has been off opioid
sedation for 24 hours or at 28 days
*Main screening for patient if patient has not been screened at day −1 or confirmation of eligibility if patient has been screened at day −1.
†Informed consent will take place if possible between 24 and 48 hours of constipation (at day −1) and if not obtained at day −1 will be
obtained at day 0 (48 hours or more of constipation).
Day −1, between 24 and 48 hours of constipation;
Day 0, 48 hours or more of constipation; PerLR, personal legal representative; ProLR, professional legal representative.
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the trial statistician. Appropriate block sizes will be
uploaded to InForm (Oracle, California, USA), the
study electronic data capture system, prior to the start of
the study.
A patient’s next of kin will be approached by the
recruiting research nurse when the patient is approach-
ing constipation, that is, after 24 hours of constipation
while the patient is receiving an opioid infusion and the
inclusion and exclusion criteria have been met. The trial
outline and information sheet will be given to the
patient’s next of kin. Provisional written informed
consent from the next of kin will be taken for the
patient to enter the trial following 48 hours of constipa-
tion. Ideally patients will be enrolled immediately after
48 hours, but the enrolment period will remain open
following this to account for delays in screening and
gaining consent. If consent has not been obtained
between 24 and 48 hours of constipation, it will be
sought at 48 hours or later and before the patient is ran-
domised into the trial or has any blood samples or data
taken for the trial.
Eligible participants will be allocated online to the
next available treatment code in the appropriate ran-
domisation list.
Blinding
When a patient is randomised to the trial, the research
nurse will draw up the study drug or placebo into a
syringe and the syringe will be labelled to meet the
standard hospital requirements before being adminis-
tered to the patient by the research nurse. The research
nurse will remain the only non-blinded member of the
team. The bedside nurse, clinical medical team, investi-
gators and the data collection team will be blinded
throughout the study.
A randomisation list will be supplied to each hospital
pharmacy to allow emergency non-blinding if needed
and requested by the local investigators. The local inves-
tigators should aim to discuss the need for non-blinding
with the trial coordinator or Chief Investigator before-
hand if possible, but will have access to a mechanism
that permits rapid non-blinding should they feel this is
necessary and be unable to contact the study team.
Local standard operating procedures (SOPs) describing
the emergency non-blinding procedure will be in place.
This will be an extremely unlikely situation.
METHODS: DATA COLLECTION, MANAGEMENT AND
ANALYSIS
Data collection methods
Participants will be followed up daily while in the ICU to
ascertain survival status at 28 days postrecruitment and
hospital discharge. Routinely collected clinical data (car-
diovascular, respiratory, renal and GI physiological vari-
ables as well as haematological, biochemical and
microbiological blood test results) will be recorded on a
daily basis during this time and entered directly by
blinded data collection staff onto trial-speciﬁc web-based
electronic case report forms (eCRFs).
Data management
Data management will be through the InForm ITM
(Integrated Trial Management) System maintained at
Imperial Clinical Trials Unit. All personal identiﬁable
data, including those from screened patients, will be
kept securely in the local site ﬁles and will not be
uploaded to the main trial database. InForm generates
automatic alerts for missing and invalid data or data that
do not conform to the rules established for that data
type. There is an electronic audit trail for all data
changes. In addition, the central coordinating site will
visit local recruiting sites to ensure compliance with the
protocol, Good Clinical Practice and local regulatory
compliance as well as source data veriﬁcation.
Statistical methods
Basic descriptive methods will be used to present the
data on study participants, trial conduct, clinical out-
comes and safety (in total and for each study group sep-
arately). For the primary end point, Cox regression will
be used to assess the effect of treatment group on time
to rescue-free laxation with ICU included in the model
as a random effect to account for stratiﬁcation.
Kaplan-Meier survival curves will also be presented. All
efﬁcacy analyses will be on an intention-to-treat basis.
METHODS: MONITORING
Data monitoring
The Trial Steering Committee (TSC) with an independ-
ent Chair, members and two patient and public repre-
sentatives will be responsible for overseeing the progress
of the trial, and will convene six-monthly.
An independent Data Monitoring Committee (DMC)
will meet six-monthly to review ongoing recruitment,
protocol compliance, safeguard the interests of trial par-
ticipants, assess the safety and efﬁcacy of the interven-
tions during the trial and monitor the overall conduct of
the clinical trial. A separate charter has been drawn up
deﬁning their exact remit and criteria for reporting to
the TSC. There will be six-monthly meetings of the
DMC.
There are no plans for interim analysis. If, in the
opinion of the Chief Investigator or DMC, clinical events
indicate that it is not justiﬁable to continue the trial, the
TSC may terminate the trial following consultation with
the Sponsor.
Harms
The trial is being conducted on critically ill patients
requiring mechanical ventilation. Morbidity and mortal-
ity may be expected as a result of their underlying
illness. Deaths will, therefore, only be reported as severe
adverse events when the investigator deems the event to
be related to the administration of the study drug.
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Details of clinical outcomes will be routinely collected in
the eCRF.
All adverse events will be reported. Further guidance
will be available from the study coordination centre.
Non-serious adverse reactions such as toxicities,
whether expected or not, will be recorded in the toxicity
section of the relevant case report form and sent to the
study coordination centre within 1 month.
Fatal or life-threatening SAEs and suspected unex-
pected serious adverse reactions will be reported on the
day that the local site is aware of the event. The nature
of event, date of onset, severity, corrective therapies
given, outcome and causality (ie, unrelated, unlikely,
possible, probably, deﬁnitely) will be recorded.
An SAE form will be completed and entered in the
eCRF for all SAEs within 24 hours of the local site
becoming aware of the event. This will automatically
send alert emails to the Chief Investigator, the Project
Manager and the Sponsor. However, relapse, organ
failure and death due to the underlying clinical condi-
tion (see deﬁnitions above) and hospitalisations for
elective treatment of a pre-existing condition do not
need reporting as SAEs.
Auditing
The study may be subject to inspection and audit by
Imperial College Academic Health Science Centre
under their remit as Sponsor, the Study Coordination
Centre and other regulatory bodies to ensure adherence
to Good Clinical Practice (GCP).
ETHICS AND DISSEMINATION
Research ethics approval
The trial protocol, the patient and PerLR information
sheets, and consent forms have been reviewed and
approved by the Harrow Research Ethics Committee
(REC Reference 14/LO/2004). Clinical Trial
Authorisation from the Medicines and Healthcare
Products Regulatory Agency has been obtained.
Protocol amendments
Proposed amendments to the protocol and aforemen-
tioned documents will be submitted to the REC for
approval as instructed by the Sponsor. Amendments
requiring REC approval may be implemented only after
a copy of the REC’s approval letter has been obtained.
Amendments that are intended to eliminate an apparent
immediate hazard to participants may be implemented
prior to receiving Sponsor or REC approval. However, in
this case, approval must be obtained as soon as possible
after implementation. The regulatory authorities and
REC will be sent annual progress reports and informed
about the end of trial, within the required timelines.
Consent
As patients will be sedated with opioids to facilitate
mechanical ventilation, it will not be possible to obtain
prospective consent from the patient at the time of
enrolment. As all the study drugs are already routinely
used in the management of constipation, there is
minimal extra risk from participation in this study.
PerLR consent
As the patient is unable to give consent, informed
consent will be sought from the patient’s PerLR who
may be a relative, partner or close friend. The PerLR
will be informed about the trial by the responsible clin-
ician or a member of the research team and provided
with a copy of the PerLR Information Sheet and asked
to give an opinion as to whether the patient would
object to taking part in such medical research. The
PerLR will be approached following 24 hours of OIC
and will be given a further period of time to consider
the patient’s participation in the study. If the PerLR
decides that the patient would have no objection to par-
ticipating in the trial, they will be asked to sign the
PerLR Consent Form that will then be counter signed by
the responsible member of the research team. The
PerLR will retain a copy of the signed consent form.
The patient, if still suffering from OIC, will then be suit-
able for entry into the trial at 48 hours of OIC. Patients
who laxate between 24 and 48 hours will not be entered
into the trial, but routine data collected as part of their
intensive care stay may be compared to the study group.
Professional legal representative consent
If the patient is unable to give informed consent, and
attempts to meet and discuss with a PerLR have failed,
then a doctor who is not connected with the conduct of
the trial may act as a professional legal representative
(ProLR). The doctor will be informed about the trial by
a member of the research team and given a copy of the
ProLR Covering Statement. If the doctor decides that
the patient is suitable for entry into the trial, they will
then be asked to sign the ProLR consent form.
Subsequently, if a relative, partner or close friend visits
the patient before he or she has regained consciousness,
then they should be informed about the patient’s partici-
pation and also informed about the retrospective
consent process.
Retrospective patient information
If and when the patient recovers and they regain the
capacity to understand the details of the trial, a member
of the research team will inform them of their participa-
tion in the trial. The patient will be given a copy of the
Patient Information Sheet. The patient will be asked for
consent to continue participation in the trial and to sign
the Retrospective Consent Form. If the patient does not
want to continue participation in the study, they will be
given the choice of having the already collected data
and samples excluded from the ﬁnal analysis.
The right of the participant or their PerLR to refuse
to participate without giving reasons must be respected.
After the participant has entered the trial, the clinician
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remains free to give alternative treatment to that speci-
ﬁed in the protocol at any stage if he/she feels it is in
the participant’s best interest, but the reasons for doing
so should be recorded. In these cases, the participants
remain within the study for the purposes of follow-up
and data analysis. All participants are free to withdraw at
any time from the protocol treatment without giving
reasons and without prejudicing further treatment.
Confidentiality
Participants’ identiﬁcation data (initials and date of
birth) will be required for the registration process. The
Study Coordination Centre will preserve the conﬁdenti-
ality of participants taking part in the study and is regis-
tered under the Data Protection Act.
The investigator will ensure that the participants’
privacy is maintained. On the eCRF or other documents
submitted to the Sponsor, participants will be identiﬁed
by a participant ID number only. Documents that are
not submitted to the Sponsor (eg, signed informed
consent forms) will be kept in a strictly conﬁdential ﬁle
by the investigator.
The investigator shall permit direct access to partici-
pants’ records and source documents for the purposes
of monitoring, auditing or inspection by the Sponsor,
authorised representatives of the Sponsor, regulatory
authorities and RECs.
Access to data
The investigator will retain essential documents until
notiﬁed by the Sponsor, and at least for 10 years after
study completion, as per the Sponsor’s SOPs. Participant
ﬁles and other source data (including copies of proto-
cols, CRFs, original reports of test results, correspond-
ence, records of informed consent and other
documents pertaining to the conduct of the study) will
be kept for the maximum period of time permitted by
the institution. Documents will be stored in such a way
that they can be accessed/data retrieved at a later date.
Consideration will be given to security and environmen-
tal risks.
No study document will be destroyed without prior
written agreement between the Sponsor and the investi-
gator. Should the investigator wish to assign the study
records to another party or move them to another loca-
tion, written agreement will be obtained from the
Sponsor.
Source documents include original documents related
to the trial, to medical treatment and to the history of
participants, and will be maintained to allow reliable
veriﬁcation and validation of the trial data.
Disseminated policy
All publications and presentations relating to the study
will be authorised by the Trial Management Group.
Authorship will be determined according to the inter-
nationally agreed criteria for authorship (http://www.
icmje.org). Authorship of parallel studies initiated
outside of the Trial Management Group will be accord-
ing to the individuals involved in the project but must
acknowledge the contribution of the Trial Management
Group and the Study Coordination Centre.
Data and all appropriate documentation will be stored
for a minimum of 10 years after the completion of the
study, including the follow-up period.
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